BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 2236458)

  • 1. A clomipramine dosage reduction study in the course of long-term treatment of obsessive-compulsive disorder patients.
    Pato MT; Hill JL; Murphy DL
    Psychopharmacol Bull; 1990; 26(2):211-4. PubMed ID: 2236458
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fluvoxamine versus clomipramine in the treatment of obsessive compulsive disorder: a multicenter, randomized, double-blind, parallel group comparison.
    Freeman CP; Trimble MR; Deakin JF; Stokes TM; Ashford JJ
    J Clin Psychiatry; 1994 Jul; 55(7):301-5. PubMed ID: 8071291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Symptoms and physiologic manifestations in obsessive compulsive patients before and after treatment with clomipramine.
    Hoehn-Saric R; McLeod DR; Zimmerli WD; Hipsley PA
    J Clin Psychiatry; 1993 Jul; 54(7):272-6. PubMed ID: 8335655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clomipramine hydrochloride in childhood and adolescent obsessive-compulsive disorder--a multicenter trial.
    DeVeaugh-Geiss J; Moroz G; Biederman J; Cantwell D; Fontaine R; Greist JH; Reichler R; Katz R; Landau P
    J Am Acad Child Adolesc Psychiatry; 1992 Jan; 31(1):45-9. PubMed ID: 1537780
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clomipramine and obsessive compulsive disorder: a placebo-controlled double-blind study of 32 patients.
    Greist JH; Jefferson JW; Rosenfeld R; Gutzmann LD; March JS; Barklage NE
    J Clin Psychiatry; 1990 Jul; 51(7):292-7. PubMed ID: 2195006
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clomipramine, clonazepam, and clonidine treatment of obsessive-compulsive disorder.
    Hewlett WA; Vinogradov S; Agras WS
    J Clin Psychopharmacol; 1992 Dec; 12(6):420-30. PubMed ID: 1474179
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Prospective follow-up over a 12 month period of a cohort of 155 patients with obsessive-compulsive disorder: phase III National DRT-TOC Study].
    Hantouche EG; Bouhassira M; Lancrenon S
    Encephale; 2000; 26(6):73-83. PubMed ID: 11217541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mirtazapine for obsessive-compulsive disorder: an open trial followed by double-blind discontinuation.
    Koran LM; Gamel NN; Choung HW; Smith EH; Aboujaoude EN
    J Clin Psychiatry; 2005 Apr; 66(4):515-20. PubMed ID: 15816795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lack of efficacy of low doses of quetiapine addition in refractory obsessive-compulsive disorder.
    Sevincok L; Topuz A
    J Clin Psychopharmacol; 2003 Oct; 23(5):448-50. PubMed ID: 14520120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preliminary results from a multicenter trial of clomipramine in obsessive-compulsive disorder.
    DeVeaugh-Geiss J; Landau P; Katz R
    Psychopharmacol Bull; 1989; 25(1):36-40. PubMed ID: 2672070
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clomipramine in obsessive-compulsive disorder: clinical response and plasma levels.
    Mavissakalian MR; Jones B; Olson S; Perel JM
    J Clin Psychopharmacol; 1990 Aug; 10(4):261-8. PubMed ID: 2286699
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A controlled comparison of adjuvant lithium carbonate or thyroid hormone in clomipramine-treated patients with obsessive-compulsive disorder.
    Pigott TA; Pato MT; L'Heureux F; Hill JL; Grover GN; Bernstein SE; Murphy DL
    J Clin Psychopharmacol; 1991 Aug; 11(4):242-8. PubMed ID: 1918422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Results of a double-blind placebo controlled trial of a new serotonin uptake inhibitor, sertraline, in the treatment of obsessive-compulsive disorder.
    Chouinard G; Goodman W; Greist J; Jenike M; Rasmussen S; White K; Hackett E; Gaffney M; Bick PA
    Psychopharmacol Bull; 1990; 26(3):279-84. PubMed ID: 2274626
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical predictors of treatment response in obsessive compulsive disorder: exploratory analyses from multicenter trials of clomipramine.
    DeVeaugh-Geiss J; Katz R; Landau P; Goodman W; Rasmussen S
    Psychopharmacol Bull; 1990; 26(1):54-9. PubMed ID: 2196627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of drug treatment response in obsessive-compulsive disorder.
    Ravizza L; Barzega G; Bellino S; Bogetto F; Maina G
    J Clin Psychiatry; 1995 Aug; 56(8):368-73. PubMed ID: 7635854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Six-year follow-up after exposure and clomipramine therapy for obsessive compulsive disorder.
    O'Sullivan G; Noshirvani H; Marks I; Monteiro W; Lelliott P
    J Clin Psychiatry; 1991 Apr; 52(4):150-5. PubMed ID: 2016246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nicotine treatment of obsessive-compulsive disorder.
    Lundberg S; Carlsson A; Norfeldt P; Carlsson ML
    Prog Neuropsychopharmacol Biol Psychiatry; 2004 Nov; 28(7):1195-9. PubMed ID: 15610934
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clomipramine treatment of obsessive compulsive symptomatology in schizophrenic patients.
    Zohar J; Kaplan Z; Benjamin J
    J Clin Psychiatry; 1993 Oct; 54(10):385-8. PubMed ID: 7903293
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fluvoxamine in obsessive-compulsive disorder: similar efficacy but superior tolerability in comparison with clomipramine.
    Mundo E; Rouillon F; Figuera ML; Stigler M
    Hum Psychopharmacol; 2001 Aug; 16(6):461-468. PubMed ID: 12404554
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A predictive study of obsessive-compulsive disorder response to clomipramine.
    Alarcon RD; Libb JW; Spitler D
    J Clin Psychopharmacol; 1993 Jun; 13(3):210-3. PubMed ID: 8354737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.